ZVSA
ZyVersa Therapeutics Inc (ZVSA)
Healthcare • NASDAQ • $0.19-4.95%
- Symbol
- ZVSA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.19
- Daily Change
- -4.95%
- Market Cap
- $1.56M
- Trailing P/E
- N/A
- Forward P/E
- -0.04
- 52W High
- $1.67
- 52W Low
- $0.11
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.79
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was found…
Company websiteResearch ZVSA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.